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Background and objectives: FIFA’s anti-doping strategy relies on education and prevention. A worldwide
network of physicians guarantees doping control procedures that are straightforward and leave no place
for cheating. FIFA actively acknowledges its responsibility to protect players from harm and ensure equal
chances for all competitors by stringent doping control regulations, data collection of positive samples,
support of research, and collaboration with other organisations. This article aims to outline FIFA’s
approach to doping in football.
Method: Description of FIFA’s doping control regulations and procedures, statistical analysis of FIFA
database on doping control, and comparison with data obtained by WADA accredited laboratories as for
2004.
Results: Data on positive doping samples per substance and confederation/nation documented at the
FIFA medical office from 1994 to 2005 are provided. According to the FIFA database, the incidence of
positive cases over the past 11 years was 0.12%, with about 0.42% in 2004 (based on the assumption of
20 750 samples per year) and 0.37% in 2005. Especially important in this regard is the extremely low
incidence of the true performance enhancing drugs such as anabolic steroids and stimulants. However,
there is a need for more consistent data collection and cross checks among international anti-doping
agencies as well as for further studies on specific substances, methods, and procedures. With regard to
general health impairments in players, FIFA suggests that principles of occupational medicine should be
considered and treatment with banned substances for purely medical reasons should be permitted to
enable players to carry out their profession. At the same time, a firm stand has to be taken against
suppression of symptoms by medication with the aim of meeting the ever increasing demands on football
players.
Conclusion: Incidence of doping in football seems to be low, but much closer collaboration and further
investigation is needed with regard to banned substances, detection methods, and data collection
worldwide.
T
he ongoing debate and controversies concerning doping
(that is, the list of prohibited substances and procedures,
and sanctions used in amateur and professional sport)
has raised public awareness of a problem that has not been
fully appreciated during the rapid development of various
sports disciplines.
It is only 38 years since drug testing was first introduced
at the1968 Olympic Games in Mexico City following
amfetamine and nicotinyl tartrate related deaths of a
number of cyclists at the 1960 Summer Olympic Games in
Rome and the 1967 Tour de France. Regular doping
controls have been conducted since, but these controls
have failed to prevent sportsmen and sportswomen from
taking performance enhancing drugs both during and out
of competition. Regrettably, banned and harmful sub-
stances are openly available, even without prescription.
Drugs such as nandrolone can be purchased over the
internet in unlimited quantities. In recent years, an
increasing number of positive samples and cases of so-
called recreational drugs, such as marijuana and cocaine,
have been observed and need to be addressed accordingly.
In addition, media reports may encourage those competing
at lower levels of sport to experiment in the use of such
substances without considering the possible side effects
and medical complications, let alone the legal consequences
of their actions.
Sporting associations, including the Fédération
Internationale de Football Association (FIFA), have stated
that the fundamental aims of doping controls and anti-
doping policies are to:
N uphold and preserve the ethics of sport
N safeguard the physical health and mental integrity of the
players
N ensure that all competitors have an equal chance.
FIFA introduced doping controls in 1970 to ensure that the
results of national and international matches were a fair
reflection of the ability of those taking part. The FIFA Sports
Medical Committee is responsible for implementing doping
controls at all FIFA competitions and also for coordinating with
confederations and member associations. The overall manage-
ment of doping controls is conducted by the FIFA administra-
tion (Medical Office and the FIFA Sports Medical Committee).
Over the past 12 years, the FIFA Medical Assessment and
Research Centre (F-MARC) has developed a worldwide
network of specialists who are involved in the educational
process within the confederations and national associations
as well as in practical performance of doping controls for
national, international, and FIFA competitions. The medical
doctors/sports physicians, following their Hippocratic Oath as
well as their professional and ethical values, play key roles in
FIFA’s long term strategy in the fight against doping. Many
of these doctors are also team physicians in their national
associations.
Abbreviations: DCO, doping control officer; EPO, erythropoietin; FIFA,
Fédération Internationale de Football Association; F-MARC, FIFA
Medical Assessment and Research Centre; hGH, human growth
hormone; IOC, International Olympic Committee; TUE, therapeutic use




The fight against doping in football focuses on education
and prevention with regular in-competition and out-of-
competition controls. In past years, approximately 15 000
doping controls were performed annually on footballers, with
over 20 000 performed in both 2004 and 2005. FIFA
articulated its unyielding position in the fight against doping
prior to the world cup competition in both 1998 and 2002
(FIFA Magazine May 2002)1 and reinforced its strategy in the
FIFA Magazine in March 2004.2
Physicians demonstrated their strong support of the FIFA
long term strategy in its fight against doping before the 2002
FIFA World Cup Japan/Korea. The team physicians of all 32
finalists signed a joint declaration in the fight against doping,
supporting FIFA’s decision to introduce routine blood
sampling to analyse for blood doping and erythropoietin
(EPO). This was a firm message to the football community
and demonstrated the excellent collaboration and coopera-
tion between the FIFA Sports Medical Committee and the
team physicians taking care of the players before and during
the competition. The team physicians of all the finalists of the
2006 FIFA World Cup Germany again reinforced the fight
against doping with a joint declaration signed on 5 March
2006 to keep this unique event free of doping.
DEFINITION
Doping is defined as any attempt by a player, either
themselves or at the instigation of another person such as
manager, coach, trainer, doctor, physiotherapist, or masseur,
to enhance mental and physical performance non-physiolo-
gically or to treat ailments or injury—when this is medically
unjustified—for the sole purpose of taking part in a
competition. This includes using (taking or injecting),
administering, or prescribing prohibited substances before
or during a competition. These stipulations also apply to out-
of-competition testing for anabolic steroids and peptide
hormones, and to substances producing similar effects. Any
other prohibited method (for example, blood doping) or
manipulation of collected samples is likewise classified as
doping.
The detailed definition as related to the anti-doping rule
violations is presented in the current FIFA doping control
regulations (January 2006).3 Doping contravenes the ethics of
sport, constitutes an acute or chronic health hazard for
players, and may have fatal consequences.
THE EXTENT AND SCOPE OF DOPING IN FOOTBALL
FIFA is a global organisation that unites over 250 million
footballers in 207 countries. Around 40 million of these
players are female. Currently, confederations, national
associations, or both that fall under FIFA’s management,
carry out their own doping controls at the competitions they
stage. However, the urine or blood samples, or both must be
analysed at laboratories accredited by FIFA/World Anti-
Doping Agency (WADA). These laboratories send reports on
any ‘‘chemically positive’’ A samples to the member associa-
tions, and FIFA headquarters for management and WADA
for information. Once the FIFA medical office receives a
positive A sample report, it requires follow up information
from the national association/confederation in question, or
both—that is, the results of the possible B sample decision
made by the particular disciplinary committee. If the
information is not provided, the FIFA disciplinary committee
takes appropriate action. Since the 1994 FIFA World Cup in
the USA, the FIFA Medical Office has undertaken stringent
registration of analysed samples.
A new doping control policy for FIFA competitions was
introduced at the FIFA U-17 World Championship in New
Zealand in 1999. Since then, during tournaments, two players
from each team are randomly selected to undergo doping
tests after each match. Between 1994 and 2005, 3327 doping
controls (men and women) were performed during three
consecutive FIFA world cups (USA, France, Korea/Japan),
two consecutive Olympic games (Sydney, Athens) as well as
the last Women’s World Cup (USA, 2003), the FIFA U-19 in
Thailand, the FIFA U-17 World Cup in Peru, the FIFA
Confederations Cup in Germany, the FIFA Club World Cup in
Japan, the FIFA Beach Soccer World Cup in Brazil, the FIFA
U-20 World Cup in the Netherlands, and FIFA World
Championship in Futsal, Chinese Taipei, as well as during
the World Cup 2006 preliminaries. Only four samples tested
positive during this period: one for ephedrine and pseudoe-
phedrine in 1994 one for cannabis and one for nandrolone
during the FIFA World Youth Championship 2003 held in the
United Arab Emirates, and one for ephedrine in Angola. This
reflects an overall incidence of 0.12% positive cases over the
past 11 years. The extremely low incidence of positive cases
during FIFA competitions indirectly confirms the FIFA long
term strategy in the fight against doping: that education and
prevention play a key role in keeping high profile competi-
tions free of doping.
It can only be assumed that team sports such as football
are not as prone to misuse of performance enhancing
substances as are individual sports. During the 2004
Olympic Games in Athens, there were 27 positive cases—all
in individual athletes and none in any team sport partici-
pants. It might be hypothesised that the close collaboration of
the team sport medical committees since the 2000 Olympic
Games in Sydney, positively influenced the attitude of
fairplay among team sports during the Olympic Games in
Athens.
Close collaboration between accredited laboratories, the
reporting system, and the central control system is an
important tool for statistical recording of the extent of
doping in football in the future. Although several prominent
footballers have tested positive for drugs in recent decades,
the true extent of the problem is unknown. Even if we
assume that doping is still not a major issue in team sports
such as football, any estimation of the problem can be
considered as merely an unscientific hypothesis or specula-
tion. To meet the challenges brought about by this situation,
FIFA has taken action to develop closer collaboration
between the medical committees of the various confedera-
tions. In October 1999, the FIFA Sports Medical Committee
and the Union of European Football Associations (UEFA)
Medical Committee met to discuss the latest sports medicine
issues with the aim of not only combating doping but also
developing educational programmes designed to meet the
fundamental objectives outlined above.
Similar meetings have been conducted between the
representatives of the FIFA Sports Medical Committee and
the medical committees of the Confederation of North,
Central American and Caribbean Association Football
(CONCACAF) (North and Central America, 2000, 2001),
Asian Football Confederation (AFC) (Asia, 2001, 2002, 2005),
and Confederation Africaine de Football (CAF) (Africa, 2003,
2004). During 2005, meetings were conducted with the newly
established Oceania Football Confederation (OFC) Sports
Medical Committee and Confederación sudamericana de
Fútbol (CONMEBOL) with the aim of harmonising doping
control procedures, improving the understanding of the
scientific background of doping, and enhancing the FIFA
network of doping control officers (DCOs) who fulfil
educational duties as a part of their responsibilities.
According to the statistics of the International Olympic
Committee (IOC) (until 2003) and WADA accredited
laboratories (as of 2004), approximately 20 750 doping
controls are performed annually on football players. The
majority of the controls are done in Europe and North and
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South America. The numbers of doping controls continue to
increase in the other confederations. In this respect, FIFA
developed its own database to keep records on the substances
being reported as positive to allow online control of
management of these samples within the different confed-
erations and member associations. During 2004 and 2005, 88
(0.42% based on the assumption of 20 750 samples per year)
and 78 (0.37%) positive samples, respectively, were registered
at FIFA (fig 1). The increase is probably because of improved
reporting systems used by the laboratories as a result of the
implementation of WADA (March 2004). The majority of the
positive cases were detected or reported by the European
laboratories which receive most of their samples from the
European national associations (figs 2 and 3).
Following FIFA’s 2003 meeting in Zurich with medical
representatives of the Olympic Team Sports Federations and
representatives from WADA accredited laboratories, it was
possible to obtain reliable data on analyses of doping samples
performed by the WADA accredited laboratories (fig 4). There
was quite a discrepancy in the numbers of samples analysed
in the laboratories for football (FIFA) ranging from 42
analyses in Seoul to 4159 in Rome. Analysis of these data
might influence the future strategy of the distribution of the
samples to the laboratories. Knowledge of the total number
of football samples analysed during the year 2004 allows
calculation of the incidence of positive samples in total
(0.42%), and the distribution and calculation of incidence in
the different confederations of FIFA (table 1), and the most
commonly found prohibited substances (table 2). The
analyses presented do not include the applications for
therapeutic use exemption (TUE) or the pending T/E
(testosterone/epitestosterone) ratio cases. These cases are
extremely difficult to manage and have motivated F-MARC
to undertake a new research study in collaboration with the
WADA accredited laboratory in Lausanne for direct proof of
testosterone in urine. This study is currently underway.
The relatively low incidence of positive doping samples,
especially for the true performance enhancing drugs such as
anabolic steroids and stimulants, support the assumption
that there is no evidence of systematic doping. Other
important support for the assumption for no evidence of
systematic doping has been provided by UEFA (2005/2006
Champions League competition). All 32 participating teams
have undergone unannounced doping controls in their
training camps. Ten players per team were tested by UEFA
medical doctors. All 320 samples were declared negative.
The newly developed FIFA database for management of all
samples collected worldwide allows tracking the records of
DCOs and has proved to be an extremely useful tool for
following up cases, particularly the less experienced FIFA
member associations. As of January 2006, this database
allows tracking each positive sample with the aim of having
the final decision of the member association’s disciplinary
committee no later than 90 days after the analysis of the B
sample.
The FIFA database will allow a continuous cross-check
with the WADA database (ADAMS, Anti-Doping And
Management System), once that is operational, not only to
control the reporting system of the WADA accredited
laboratories, but also to allow prospective studies on
sanctions related to the different substances, the severity of
the violation, or both.
LIST OF PROHIBITED SUBSTANCES
Like most major governing bodies of sports and the IOC, FIFA
has drawn up lists of both prohibited doping substances and
methods. The categories of prohibited substances and
methods are approved by the FIFA Sports Medical
Committee and follow the Prohibited List and International
Standards published by the WADA. The most recent FIFA
doping control regulations and list of banned substances
(January 2006) are divided into three main sections contain-
ing different categories of prohibited drugs and methods (box
1). Additional methods and substances such as stimulants,
narcotics, cannabinoids, and glucocorticosteroids are
included for in-competition testing. The 2006 list includes
specified substances that are examined for monitoring
purposes and are particularly susceptible to unintentional
anti-doping violations because of their general availability in






























Figure 1 Doping statistics per substance (excluding testosterone/



























Figure 2 Positive doping samples by confederation (excluding









































































Figure 3 Positive doping samples for Europe by country (excluding
testosterone/epitestosterone (T/E)): FIFA 2004 and 2005.
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successfully misused as doping agents. A doping violation
involving such substances may result in a reduced sanction
provided that the (FIFA Doping Control Regulations p. 33):
athlete can establish that the use of such specified
substances was not intended to enhance sports perfor-
mance
An extensive list for each category of prohibited substances is
provided by FIFA in the annual doping control regulations.
These lists are always followed by the words ‘‘and related
substances’’ to include all substances that have a similar
chemical structure and/or pharmacological effect.
Even though the majority of the drugs described are
banned in football, some categories are more capable of
enhancing a player’s performance than others and, as such,
may well be used in our sport. Two categories not commonly
used by players are narcotic analgesics and diuretics. The
narcotic analgesics used are mainly from the opioid family—
for example, morphine. Diuretics are used as masking agents
in certain sports. Both of these categories are contraindicated
for the types of exercise that footballers have to perform on
the field over 90 minutes. Three categories that could involve
footballers are stimulants, anabolic agents, and peptide
hormones.
CURRENT DOPING CONTROL REGULATIONS
Cooperation between the confederations and national
associations
A comparative study of the existing doping control regula-
tions issued by the FIFA confederations in 1999 showed a
high level of agreement as far as the lists of banned
substances and methods were concerned. This was because
the confederations simply decided to adopt the current FIFA
doping control regulations. A detailed survey of the doping
control regulations issued by national football associations in
1999, however, revealed some differences in the procedures
and inclusion of certain substances in the categories of
prohibited substances.
Following this comparative study, the FIFA Sports Medical
Committee and F-MARC issued a proposal to the executive
committee to harmonise the doping control regulations of all
national associations and to adopt the list of prohibited
substances and methods. Following FIFA’s executive com-
mittee decision, the FIFA congress ratified the decision at its
Ordinary Congress in Seoul (May 2002), which paved the
way for the decision of the FIFA Extraordinary Congress in
Doha/Qatar (December 2003). This follows the method of
individual case management and will extend expulsion
sanctions by the disciplinary committees of national associa-
tions for all international matches, and vice versa.
Stringent rules of procedure
Although the in-competition Doping Control Regulations
outline a clear procedure, the out-of-competition controls
have not been performed routinely in football mainly because
the professional football player is ‘‘in competition’’ almost
the entire year except during brief seasonal breaks (two to
four weeks) or if in rehabilitation after severe injury.
FIFA and UEFA jointly produced a set of regulations for
out-of-competition doping controls for the first time before
EURO 2000. About one month before the tournament, all the
competing countries were informed that unannounced
doping controls might be carried out at training camps and










































































































































Figure 4 Numbers of samples
analysed in 2004 at WADA accredited
laboratories for doping.
Table 1 2004 doping statistics (per confederation) from
WADA accredited laboratories (excluding T/E)
Football
confederation Samples Positive Incidence (%)
AFC 1 058 4 0.38
CAF 715 2 0.28
CONCACAF 275 0 0.00
CONMEBOL 3 993 17 0.42
OFC 226 1 0.44
UEFA 14 483 64 0.44
Total 20 750 88 0.42
Table 2 Substance per positive sample from
WADA accredited laboratories (2004)
Substance Sample Incidence (%)
Cannabis 37 0.18
Cocaine 30 0.14
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select four national teams, two DCOs (one from UEFA and
one from FIFA) visited the training camps in question at
around 11 am and immediately reported to the national
team’s head of delegation. The head of delegation was
requested to find a suitable location for collecting the
required samples. The players to be tested—four per team—
were then drawn by lots and the doping control procedure
was carried out by the UEFA and FIFA doctors immediately
afterwards. The experience of these out-of-competition tests
showed the need for a much greater level of cooperation
between national associations, confederations, and FIFA to
ensure that procedures for standard doping controls and
unannounced out-of-competition controls were brought
more closely into line.
A similar procedure for out-of-competition controls was
performed in training camps before the FIFA World Cup 2002
(Korea/Japan) and Euro 2004 (Portugal). The procedure
proved to be feasible and the compliance of involved teams
and individual players was 100%. Out-of-competition, unan-
nounced controls are planned prior to the FIFA World Cup
Germany 2006.
The need to use a medical doctor as a DCO
Although some sporting organisations and anti-doping
agencies continue to employ coordinators who are not
medical doctors, FIFA and its member confederations insist
on physicians for doping controls. This requirement requires
closer analysis.
Players from teams selected to undergo a doping test are
required to provide details of any treatment with medicines
from 7 weeks to 72 hours before the test or the competition
in question. All medicines that a player has received must be
listed together with details of the method of administration,
dosage, and medical indications. The information declared on
the forms used for this purpose is covered by patient
confidentiality and may not be communicated to non-
medical personnel (for example, the general secretary of the
football association concerned, the player’s coach or the
club’s general manager) unless the A sample tests positive.
For confidentiality reasons alone, it is essential that the DCO
is a physician with appropriate qualifications for this
position.
Clinical studies show that until recently most of the doping
substances encountered have been, as a general rule, drugs
developed for therapeutic purposes and are primarily used for
medical therapy. Today, however, an increasing number of
substances are being developed for the sole purpose of
doping, and no studies have been conducted into their
clinical effectiveness. This is an important reason why
specially trained physicians, working in close cooperation
with laboratory specialists, should serve as doping control
coordinators. The doctor not only has to carry out the control
procedure, but also has an educational function before,
during, and after the doping control.
PROHIBITED SUBSTANCES PRESCRIBED FOR
MEDICAL REASONS (TUE)
If there is any doubt regarding the appropriate therapeutic
treatment of a player who has a medically confirmed
pathological condition, drugs containing prohibited or
partially prohibited substances could be permitted in excep-
tional cases if:
N the player’s health would be impaired if the prohibited
drug were withheld
N no performance enhancement could result from the
prohibited substance being administered as medically
prescribed
N no permitted or practical alternative drug is available in
place of the prohibited substance.
In such a situation, a player or his or her doctor must request
for a TUE by submitting a formal application to the FIFA
Doping Control Sub-Committee. Strict confidentiality is
necessary and guaranteed.
FIFA has become part of an international network in this
field, initiated by the Australian Sports Drug Medical
Advisory Committee (ASDMAG), and will be able to draw
on the accumulated body of knowledge from other team
sports, WADA, and individual cases. The TUE applications are
managed by the FIFA Doping Control Sub-Committee. A
copy of approval or rejection is automatically sent to WADA
for information and possible appeal.
LABORATORY ANALYSIS OF SAMPLES
Chain of custody
The laboratories that are in charge of doping analysis
throughout the world are all specialised and well equipped
institutions, empowered by their national sporting autho-
rities to analyse the urine samples received from sporting
authorities. WADA has established an accreditation system
for such laboratories. A total of 33 laboratories were fully
accredited in 2005 (box 2). This accreditation is based on
quality control checks performed annually on each labora-
tory. The main objective of accreditation is to guarantee
uniform quality of analysis at laboratories all over the world.
International federations, including FIFA, use these official
laboratories for their major events and competitions. The
laboratory is requested by the governing body concerned to
analyse samples and is obliged to comply strictly with the
rules laid down in their medical codes. The laboratories treat
all samples anonymously with each sample being labelled
with a code number known only to the player and the
committee in charge of the controls. This is essential to assure
the player that the analysis is completely objective and to
avoid any undue pressure on the laboratory which analyses
the samples.
The results (negative or positive) are communicated to the
committee in charge of the controls. If the A sample is
positive, the test is performed a second time before the result
is sent to the relevant committee. A copy from the report of
Box 1 FIFA doping control regulations:
categories of banned substances and methods
Prohibited substances
N Anabolic agents
N Hormones and related substances
N b2 agonists
N Agents with antiestrogenic activity
N Diuretics and other masking agents
Prohibited methods
N Enhancement of oxygen transfer
N Chemical and physical manipulation
N Gene doping
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any positive case is simultaneously sent to the international
federation (if the committee in charge is not in charge of the
controls) and to FIFA and WADA. The committee in charge
then informs the player who then has a limited time to
request analysis of the B sample.
The sample analysis
Samples are analysed with the aim of identifying all
detectable banned substances. The equipment used is state
of the art technology designed to generate a ‘‘molecular
fingerprint’’. The technique of choice is gas (or liquid)
chromatography controlled with detectors based on mass
spectrometry. Chromatography is the first step in the analysis,
consisting of a preliminary separation in the mixture of
several natural or non-natural substances contained in each
urine extract. After the substances have been sorted, a mass
spectrometer provides a picture of the molecular structure
that can be compared with others stored in the chemical
databases of the computer that controls the entire system.
The aim of these analyses is to prove that no banned
substances are present in the urine samples provided by
‘‘clean’’ players (the vast majority: a true negative), so that a
player can then be declared negative. In positive cases, the
same technology must also deliver absolute chemical proof
that a banned substance or its degradation products (called
metabolites) are present in the urine (a true positive). Every
possible step is taken to prevent samples from erroneously
being declared positive (a false positive); in general, the
purpose of B sample analysis is to provide confirmation of the
result obtained during the first test in the presence of the
player or one the player’s representatives.
Unfortunately, not all banned substances used in sport can
be detected using this technology (a false negative). In
addition, some of them have exactly the same structure as
their natural endogenous forms and are quite difficult to tell
apart.
The T/E ratio
Widespread use of anabolic steroids in doping began in the
1980s and testosterone was one of the preferred androgenic-
anabolic agents. Until recently, it was difficult to differentiate
between synthetic and natural testosterone in the body. The
only method available was a quantitative one involving the
establishment of a ratio with another steroid called epites-
tosterone, which is similar to testosterone and is very stable
in its concentration. The normal Caucasian and African
populations have a mean ratio (testosterone to epitestoster-
one, T/E) of 1.5:1 (for males) with some variability, rising to
4:1 in rare cases. The mean ratio for Asian people is generally
lower than 1:1. A player with excessive levels of testosterone
will have a much higher ratio, resulting from an increase in
testosterone concentration. It was later decided that the
maximum permissible T/E ratio would be 6:1, and that any
ratio over this limit would be declared positive. Currently, the
limit for an adverse finding is fixed at 4:1.
In addition to the T/E ratio, monitoring of the complete
steroid profile of the player over time can also demonstrate
manipulation. This can be due to the consumption of other
steroids such as testosterone precursors which can be easily
purchased over the internet. Moreover, new laboratory
instrumentation, the isotope ratio mass spectrometer
(IRMS), allows differentiating between steroids of endogen-
ous and exogenous origin in urine. This tool, together with
retrospective data on the player, if they exist, and in some
cases, additional endocrinological investigations, will provide
the disciplinary commissions with the opportunity to make
the most accurate decision in a timely manner.
A validation study initiated in 2004 by FIFA jointly with
Swiss Anti-Doping Laboratory (LAD, the WADA accredited
laboratory in Lausanne) is in progress.
The case of nandrolone
Just before the FIFA World Cup in France in 1998, a number
of well known players tested positive for small amounts of
nandrolone metabolites in their urine. Nandrolone (chemical
name nortestosterone) is an anabolic steroid often encoun-
tered in bodybuilding doping cases. In general, this com-
pound is taken in high doses and its degradation products
(metabolites) remain detectable in urine for up to several
months. Before the 1998 World Cup, FIFA commissioned an
independent anti-doping laboratory (LAD) to carry out a
collaborative study to obtain a true picture of the situation in
football. With the agreement of national and international
bodies, every player from every team in the top national
leagues in Switzerland (A and B leagues) was tested after a
game (356 players in total over two weekends) in collabora-
tion with the Swiss anti-doping committee. The results
were compared with those obtained by testing amateur
footballers and students. Without revealing anything about
the origin of these products, the study showed some
players had nandrolone metabolites in their urine after the
game. The traces of metabolites in the urine of those players
were very small, and all were below the limits of a positive
reading.
On the basis of this study, FIFA was able to organise the
anti-doping programme for the 1998 World Cup with a
degree of assurance to provide reliable information to the
competing teams to rule out any occurrence of false positive
tests. With FIFA’s support, this study into nandrolone and its
derivate substances continued. Extraordinary variability in
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excretion was shown, making the relation between dosage,
time delay, and urine concentration critical. Involvement of a
world governing body in such a research programme is
essential if any worthwhile progress is to be made in this
area. The players can also be given the assurance that,
scientifically and ethically, they start a match on an equal
‘‘playing field’’ with their opponents as far as doping is
concerned.
THE PEPTIDE HORMONES
There are several peptide hormones in the list of prohibited
substances, of which the two most important are EPO and
the human growth hormone (hGH).
EPO
The use of EPO in sport can be established by analysing urine
by a novel method based on the biochemical properties of
EPO. EPO and its analogues are too large to be filtered by the
kidney and are easily eliminated in urine. As their concen-
trations in urine are so low there was a need for improvement
in biochemical technology to allow the detection of this
product in urine. Thus, in 2000, the WADA accredited
laboratory in Paris implemented a method based on a small
structural difference between recombinant and natural EPO
to determine whether doping had taken place. This method is
now applied in several accredited laboratories in the world.
hGH
The chemical structure of bioengineered hGH is almost
identical to the natural hormone produced by the body.
Consequently, it is particularly difficult to differentiate
between the injected and the natural hormone. Recently
developed methods use blood as a biological sample for the
determination of a specific ratio diagnostic for the use of
recombinant hGH. This new approach clearly demonstrates
the necessity to implement blood sampling for anti-doping
purposes.
Blood sampling
Recently, blood has been introduced as an alternative
biological matrix to urine for anti-doping sampling purposes.
Since 2004, blood has been recognised as absolutely
necessary for reliable results for some forbidden substances
and methods. The list of these substances and methods is not
definitive, but currently, hGH, synthetic haemoglobins, and
homologous blood transfusions can be reliably detected with
several blood matrices.
Some other blood tests are also carried out in certain
sports, not for the purpose of determining the presence of
doping, but rather as general health checks conducted in the
context of medical screening of the competitors. This has
potential for the future and could easily be introduced by
some national or international federations depending on
their structural organisation. However, this concept is more
difficult to implement in larger federations which have
players on every continent.
FIFA NETWORK OF DCOS
In cooperation with the football confederations and national
associations, FIFA has established a worldwide network of
more than 250 specially trained physicians who act as FIFA’s
DCOs. With regard to medical confidentiality and the
necessity for specific knowledge in the field, FIFA only
accepts physicians as DCOs.
To ensure ‘‘unity of doctrine’’ all DCOs attend instructional
seminars conducted by F-MARC (Professor Jiri Dvorak,
Chairman) and FIFA Doping Control Subcommittee
(Professor Toni Graf-Baumann, Chairman). Such seminars
have been held for CAF (Tunis, November 2000), AFC
(Penang, January 2001), UEFA (Zurich, January 2001),
CONCACAF (Miami, February 2001), and OFC (Auckland,
New Zealand, March 2001), and also in Tunis in January
2004, Marrakesh in November 2004, Buenos Aires in
March 2005, Oman in May 2005, Port of Spain in
December 2005, Auckland in February 2006, and Buenos
Aires in April 2006.
The DCOs, as members of the FIFA network, are currently
spread around the world. To make doping control cost
effective, the FIFA Congress followed the recommendation of
the Sports Medical Committee that DCOs are, by profession,
physicians who follow the Hippocratic Oath and their
professional laws. DCOs perform doping controls on their
national team in their country when playing against a team
from another country. The FIFA doping control procedure is
straightforward and transparent, leaving no room for
cheating or wrongdoing when all steps are performed in
the presence of representatives from both teams. This makes
the logistics easier and significantly reduces the costs
involved, particularly for qualifying matches for major
competitions.
RESEARCH
The current list of banned substances contains a number of
drugs for which there is no conclusive scientific evidence to
justify inclusion on the list. Research on selected substances
has highlighted some performance enhancing effect whereas
other references are doubtful. In view of the potentially
enormous repercussions (as demonstrated at the Sydney
Olympic Games) there are several ways of improving the
current situation.
N A database containing all currently listed substances
should be set up. This should give details on the
pharmacological background, research findings, and clin-
ical papers documenting the effects of the particular
substance.
N Borderline substances should be reconsidered on the basis
of research studies providing scientific analysis of their
effect on physical and psychological performance as well
as effect on the metabolism.
N A standard study design (double blind, randomised trials)
should be set up for substances under scrutiny, proved in
pilot projects and implemented multicentrically. The
results of such studies should form the basis for future
inclusion on the list of prohibited substances.
N Tracing and identification of masking agents.
Such initial research work might help to reduce the list of
banned substances so that the focus can be on the major
problem areas such as anabolic steroids, and peptide
hormones and related substances, such as human chorionic
gonadotrophin, hGH, and EPO. Research into nandrolone
metabolism in footballers, conducted with FIFA’s support,
eloquently documents the complexity of the problem. The
study showed that current laboratory methods cannot
distinguish between endogenous metabolism and exogenous
intake of nandrolone. Although the cut-off level of 2 ng/ml
would appear rational, it is not scientifically proved, leaving
the door wide open for discussion. Further double blind
studies are in progress in an attempt to obtain the scientific
evidence needed to end the ongoing speculation. Until then,
this cut-off level is valid and will remain in effect.
FIFA has realised and documented its responsibility by
supporting research studies that promise to enhance current
medical knowledge. A combined effort with other interna-
tional sports federations, the IOC, and anti-doping agencies
might, however, accelerate the process.
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EDUCATING THE FOOTBALL COMMUNITY ABOUT
DOPING AND PERFORMANCE
Two issues of importance with regard to education of the
football community are:
N Collaborating with team doctors
N Supplements and special nutrition
Continuous and close contact with team doctors is
necessary in countries where sports medicine is still devel-
oping and where the team doctors may not have special
training on doping issues. In view of the rapid changes in
doping with regard to both substances and methods of
administration, a constant exchange of information with all
team doctors is essential. Besides the fact of the problem,
effective procedures against doping cannot be put into
practice unless a close, trusting relationship has been
established between the team doctors and the DCOs.
With regard to above, particular attention must be paid to
food supplements and special diets that might be prescribed
for an player. Supplements or diets may contain banned
substances, which means that the player may be taking
substances (or using food supplements) without realising
that it may contain a banned substance. If the player tests
positive, it is difficult to prove that the substance(s) in
question originated in the player’s food or food supplements.
From the legal point of view, players testing positive in such
situations must bear the responsibility themselves. Here, too,
a constant flow of information between DCOs and team
doctors helps everyone keep abreast of developments in the
‘‘market’’ and prevent problems arising for players.
The recently published summary of the ‘‘Nutrition for
Football: the FIFA/F-MARC Consensus Conference’’4 clearly
states that there is no evidence to support the current
widespread use of dietary supplements in football.
Supplements should be used only on the advice of qualified
sports nutrition professionals. Football players can stay
healthy, avoid injury, and achieve their performance goals
with good dietary habits. Players should choose foods that
support and optimise both training and match performance.
What a player eats and drinks in the days and hours before a
game, as well as during the game, can influence the result by
reducing the effects of fatigue and optimising performance.
Food and fluid ingested soon after a game and training can
accelerate recovery. All players should have a nutrition plan
that takes individual needs into account.
FIFA’S COOPERATION WITH WADA
On 4 February 1999, a Lausanne declaration on doping in
sport was presented to the IOC and international sport
federations that an independent international anti-doping
agency should be established and fully operational by the
2000 Olympic Games in Sydney to coordinate the various
programmes necessary to realise the objectives. FIFA’s
medical and legal representatives have developed a close
collaboration since 1999 based on numerous meetings with
the representatives of the WADA, particularly following the
meeting of FIFA President Mr Joseph Blatter and the
Chairman of WADA, Mr Richard Pound, in Montreal in
December 2001.
FIFA’s medical and legal experts contributed significantly
to the improvement of the World Anti-Doping Code
particularly in versions 1 and 2. They insisted on having
independent expert opinion by prominent European judges
and lawyers, including the International Sports Lawyers
Association, on individual case management regarding
positive cases. This individual case management has been
confirmed as a strategy by internal studies of the medicolegal
aspects of the team sports federations based upon 184
positive samples between 1998 and 2003 in different sports.
After intensive discussions with Mr Pound, the manage-
ment of WADA, and a historic speech delivered by Mr Pound
(54th Ordinary FIFA Congress in Paris on 19 May 2004), an
informal agreement on collaboration between FIFA and
WADA was signed by the respective presidents and con-
firmed by the IOC President, Dr Jacques Rooge. Based upon
this agreement and adaptation of the FIFA Doping Control
Regulations, changes have been incorporated in the FIFA
Disciplinary Code.
LEGAL BACKGROUND
In this regard, the legal background will be briefly described.
FIFA is a private association in accordance with Article 60 ff.
Swiss Civil Code with headquarters in Zurich, Switzerland.
Consequently, FIFA is a legal person in accordance with
Swiss private law and has to comply with it when setting up
its statutes and regulations.
The principles of fault and individual case management are
essentials of Swiss sanction law and therefore have to be
considered when imposing private sanctions. Every sanction
contains a distinctive individual component, because every
sentence has to take into account the fault of the delinquent.
FIFA has been following these principles in its Doping
Control Regulations from the beginning.
To base its decisions on expertise, FIFA itself sought a legal
opinion from the Court of Arbitration for Sport (CAS) about
the extent to which WADA’s code complied with Swiss law in
September 2005.
In its legal opinion published in April 2006, CAS explicitly
confirmed FIFA’s practice of individual case management
when sanctioning doping offences. In addition, CAS noted
that FIFA’s principle of individual case management com-
plies with the World Anti-Doping Code. At the same time, the
independent sports arbitration body, with headquarters in
Lausanne (Switzerland), has also ruled that FIFA’s provi-
sions with regard to the fight against doping and the
sanctioning of doping offences are, to the greatest possible
extent, in line with the World Anti-Doping Code, and that
they are also fully in line with Swiss law. CAS also compared
FIFA’s provisions with those of the World Anti-Doping Code
in 22 main areas. In 16 points, including the definition of
doping, the strict liability principle, the list of prohibited
substances, therapeutic use exemptions, testing and analysis,
hearings, commencement of the ineligibility period, and
disqualification provisions regarding teams, CAS stated that
there were no material differences between the two sets of
regulations.
Furthermore, CAS confirmed FIFA’s attitude by stating
that neither the IOC nor WADA has the right to dictate to
FIFA as regards the latter’s disciplinary regulations for the
fight against doping and the sanctioning of doping offences.
According to CAS, international sports federations are free to
establish such provisions as they deem appropriate, especially
as CAS also noted that the World Anti-Doping Code is not
legally binding per se. CAS reported differences in six areas
between FIFA’s provisions and the World Anti-Doping Code,
although it only highlighted significant deviations in three of
these points. CAS came to the general conclusion that with
regard to the approach used to determine the level of
punishment to be imposed, there are no considerable
differences between the two sets of regulations. FIFA, as
well as WADA, are in the process of finding a consensus to
maximum and minimum of sanctions.
With regard to possibly eliminating a sanction in cases in
which athletes prove that they did not act with fault or
negligence, CAS recommended that FIFA incorporate an
appropriate provision in its regulations and not impose
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sanctions on athletes who prove that a prohibited substance
entered their body through no fault or negligence of their
own. FIFA, however, already follows such a practice by
applying the principle of guilt when sanctioning doping
offences. In addition, FIFA was advised by CAS to adapt its
regulations to clarify WADA’s right of appeal against
procedures followed in final-instance decisions. Conversely,
it was noted that with its provision regarding the statute of
limitations, the World Anti-Doping Agency’s code is not in
line with Swiss law.
This legal opinion from CAS has laid the foundations for
FIFA to make the necessary adjustments to the relevant
provisions independently. FIFA, together with WADA, under
the moderation of the Sports Minister of England, Mr R
Caborn, have discussed the points of differences in a
constructive way to reach a FIFA’s complete compliance
with WADA code. Beyond that, after being operational for
two years, it seems reasonable to reflect on the feasibility and
applicability of the World Anti-Doping Code based upon the
analysis of positive doping cases as related to the incidence and
management among the different member associations. Such
analysis is foreseen within the revision of the World Anti-
Doping Code, which was initiated by WADA in April 2006.
OCCUPATIONAL MEDICINE IN FOOTBALL: A
VISION
Occupational medicine deals with all work related aspects of
health that affect the employee’s ability to function effec-
tively: the workplace itself, the type of work, the state of
health of the employee. In addition to purely physical aspects,
social and psychological influences must also be considered.
It is easy to see that construction workers who are paid
according to how much work they complete will be subject to
greater stress than, say, a gardener or office worker employed
on standard terms. Moreover, within any occupation there
are those—often a considerable percentage—who will reg-
ularly need medicines to function properly—for example,
those with diabetes, high blood pressure, allergies, rheumatic
disorders. In such cases, any extra stress in the work
environment can easily lead to a situation where the ability
of the person to function is close to the borderline of what
can be physically expected. These people can often become
incapable of continuing in the job or of only doing so under
medical supervision and with the prescription of suitable
medicines.
There are definite limits to the level of stress under which
such people can function and it is the concern of occupational
medicine to recognise and deal with these limits.
Occupational medicine aims to point out to both employer
and employee that only under certain specified conditions
will optimum performance be possible. The conditions that
could be recommended in such cases might include changes
in the workplace, in working hours, in the pressures of the
job, or might specify regular medical treatment for the
employee—for example, prescription medicines to protect the
employee from the effects of workday stress, such as b
blockers.
If we now consider a sport such as football, a number of
examples can be identified. The proportion of players who
have allergies is similar to that in the general population, and
the treatment will be the same—that is, appropriate therapy
often involving the taking of medicines, especially during
those times of the year when the allergen count is high. But
when we are dealing with open air sports, the treatment
prescribed could lead to problems since many of the drugs
usually prescribed are on the list of banned substances (such
as corticosteroids) even though their prescription is medically
justified.
An example of an American professional international
woman player makes the situation clear. She has a relatively
rare disease that makes her blood pressure and fluid balance
subject to extreme variations; this in turn makes it impossible
for her, without medical help, to pursue her profession at the
required level. She needs ongoing treatment with a miner-
alocorticoid (fludrocortisone). However, in contrast with
those mentioned above, this medicine has neither an
anabolic nor an anti-phlogistic effect and is thus not
technically a doping substance in the true sense of the term.
This raises the question whether it really constitutes doping if
a player can perform at the expected level only after taking
such a medicine. We suggest that this is a problem that falls
within the scope of occupational medicine. If such treatment
is prescribed for genuine medical reasons and involves taking
a drug that in itself has no doping effect, then we cannot be
talking about a case of doping, rather merely of enabling a
professional player to exercise his or her normal profession.
Occasional treatment with banned substances for ‘‘bona
fide’’ medical reasons should be permitted if the facts of the
case are presented openly to the doctors in charge of the
doping control.
A quite different question is whether the ever increasing
demands faced by professional footballers, in terms of the
number of matches and tournaments in which they are
expected to play, can be compensated for by taking medicines
so that the required level of performance can be achieved over
and over again. Playing so frequently, in football as in other
sports, under circumstances necessitating more or less con-
tinual treatment with painkillers and anti-inflammatory agents,
can have serious long-term consequences that really cannot be
justified on the basis of occupational medicine or medical ethics.
In this case, the limits of doping are recognisable.
Admittedly there is no doping in the first two examples in
terms of performance enhancing drugs being taken.
However, in the sense of medical treatment being used to
suppress the symptoms of injuries and overexertion, clearly
there is an aspect of doping involved. The workplace
pressures on players in the short term lead to long term
effects being ignored. As long as the players in question and
their associations all have the same approach, only a firm
stand by sports and occupational medicine will have the
effect of providing the players with at least partial protection
What this article adds
According to the data presented, the incidence of doping in
football seems to be quite low (0.4%). The vast majority of
positive samples are due to recreational drugs. These
findings support FIFA’s strategy of education and prevention.
On the basis of principles of occupational medicine treatment
banned substances for medical reasons should be allowed to
enable players to carry out their professional obligations.
What is already known about this topic
Doping control in sports was introduced in 1968, with the
aim of upholding and preserving the ethics of sport,
safeguarding the physical and mental integrity of players,
and ensuring equal chances for all competitors. Different
approaches have been used in the fight against doping.
These approaches should ideally be based on valid data of
the true extent of doping and sound scientific knowledge of
substances, their pharmacokinetics, pharmacodynamics, and
effects, and the detection methods.
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from such long term damage. This is further reason why the
campaign against real doping must be actively pursued.
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